Study Finds Broad Suite of Plastic Additives in Baby Skincare Products — 121 Compounds Identified, 99 Quantified

Key Highlights
Introduction
Scope and methods: how the study mapped plastic additives in baby products
What the survey found: chemical groups, concentrations, and product patterns
Newly reported compounds and transformation products: the hidden chemistry
Exposure assessment: what detected concentrations mean for infants and toddlers
Toxicological context: what is known about the health effects of detected groups
Sources and pathways of contamination: how do plastic additives get into baby products?
Regulatory landscape and gaps: how current rules align with findings
Industry implications: formulation, testing, and supply chain management
Consumer guidance: practical steps parents can take now
Research needs: where science must advance
Policy options: reducing exposure at the population level
What manufacturers and regulators should monitor routinely
Balancing benefits and uncertainties: practical risk communication
Closing observations: the study’s contribution to product safety science
FAQ

Key Highlights

Analysis of 55 commercial baby skincare products detected 121 plastic additives (PAs); 99 were confirmed and quantified, with a median total PA concentration of 3,220 ng/g.
Non-phthalate plasticizers were the most abundant group (median 1,090 ng/g), followed by organophosphate esters, UV stabilizers, phthalates, synthetic antioxidants, parabens, and bisphenols.
Over 20 compounds — including emerging plasticizers and transformation products of organophosphate esters, antioxidants, and UV stabilizers — were reported in baby products for the first time, raising questions about mixture exposures during critical developmental windows.

Introduction

Parents expect baby lotions, powders, and shampoos to be mild and safe. These products are applied directly to delicate skin, often multiple times per day, and during stages when infants and toddlers are especially susceptible to chemical exposures. A systematic chemical survey now reveals that baby skincare formulations routinely contain a wide and sometimes unexpected array of plastic additives. The inventory spans legacy chemicals such as phthalates and bisphenols, commonly used replacements categorized as non-phthalate plasticizers, flame-retardant organophosphate esters, ultraviolet (UV) stabilizers, and minor but recurrent groups including synthetic antioxidants and parabens.

The findings restructure how product safety should be assessed. Rather than focusing on a handful of regulated substances, this work highlights the complexity introduced by hundreds of low-level contaminants and their transformation products. Those compounds can originate inside formulations, from packaging, or through environmental or manufacturing degradation. The presence of previously unreported transformation products underscores the need to consider chemical life cycles and not just parent compounds when evaluating consumer exposure and risk.

This article synthesizes the study’s methods and key findings, places them into a broader toxicological and regulatory context, and outlines practical implications for consumers, manufacturers, and policymakers. It addresses why transformation products matter, how exposure was estimated, and what the discovery of a chemical “soup” in baby skincare means for health protection strategies.

Scope and methods: how the study mapped plastic additives in baby products

The research applied a two-pronged analytical strategy: high-resolution mass spectrometry-based suspect screening followed by targeted quantification using reference standards. This approach allowed investigators to cast a wide net for known and suspected plastic additives and then confirm and measure those that matched available standards.

Fifty-five commercial baby skincare items were sampled, representing categories that are commonly applied to infant skin: lotions, powders, and shampoo-bath foams. Sampling prioritized products sold for infant and toddler use, reflecting market formulations parents likely apply directly to young children’s skin.

High-resolution mass spectrometry enabled detection of molecular features consistent with hundreds of additive candidates. Suspect screening uses accurate mass, isotopic patterns, fragmentation spectra, and retention time behavior to flag likely matches from comprehensive chemical lists. Where standards were available, the flagged compounds were then confirmed and quantified, yielding the subset of 99 compounds with measured concentrations.

This combined workflow is becoming standard in environmental and product chemistry because it balances the breadth of non-target discovery with the precision of targeted measurement. Importantly, suspect screening flagged more compounds than could be quantified — indicating that many contaminants remain structurally characterized only by mass spectral signatures, not by reference-confirmed identity or concentration.

What the survey found: chemical groups, concentrations, and product patterns

The study identified 121 plastic additives in total; 99 of these were confirmed and quantified. Concentration results were summarized as medians across samples and by chemical group:

Median total PA concentration: 3,220 ng/g.
Non-phthalate plasticizers: median 1,090 ng/g (largest contributor).
Organophosphate esters (OPEs): median 289 ng/g.
Ultraviolet stabilizers: median 227 ng/g.
Phthalate esters: median 205 ng/g.
Synthetic antioxidants: median 77.8 ng/g.
Parabens: median 13.9 ng/g.
Bisphenols: median 7.45 ng/g.

Several observations emerge from these numbers. First, substituting legacy phthalates with non-phthalate plasticizers has reduced some regulated compounds but introduced other classes that can be present at equal or higher abundance. Second, organophosphate esters and UV stabilizers — groups originally intended to protect plastics and polymer-containing materials — are common contaminants. Their presence suggests multiple contamination pathways: direct inclusion as functional ingredients, migration from plastic packaging, or cross-contamination from manufacturing lines.

Product-specific patterns were evident. For example, lotions tended toward higher concentrations of non-phthalate plasticizers and synthetic antioxidants, consistent with their emollient and preservative functions. Powders showed distinct profiles, occasionally enriched in UV stabilizers or organophosphate residues; this may reflect raw material differences or handling and packaging factors. Shampoo and bath foams featured a combination of surfactant-associated contaminants and low to moderate levels of the broader suite of PAs.

Concentration distributions were wide. Some products had relatively low total PA burdens, while others contained orders of magnitude higher concentrations of certain groups. That heterogeneity complicates exposure estimation, because a child’s actual intake depends heavily on product selection, frequency of use, and application rate.

Newly reported compounds and transformation products: the hidden chemistry

More than 20 compounds appeared in baby skincare formulations for the first time in this survey. These included emerging plasticizers and transformation products derived from organophosphate esters, synthetic antioxidants, and UV stabilizers.

Transformation products form when parent chemicals degrade chemically, photochemically, or biologically during production, storage, or use. They may also arise during manufacturing if a stabilizer or plasticizer interacts with other ingredients. These byproducts often have different physicochemical properties than their parents: some become more polar and mobile, some more persistent, and some more biologically active.

The detection of transformation products signals two critical realities. One, product inventories are dynamic: a measured list of parent ingredients does not capture the full set of chemicals consumers will encounter. Two, regulatory oversight and safety testing often focus on parent compounds. When new derivatives appear, they typically lack robust toxicological data, making risk assessment incomplete.

Examples from the broader literature illustrate why transformation products matter. Hydroxylated or dealkylated derivatives of organophosphate esters can differ in toxicity and persistence compared with their parental OPEs. Antioxidant breakdown products sometimes carry reactivity not present in the parent molecules. UV stabilizers can transform into smaller molecules that penetrate skin more readily. The study’s detection of these transformation products in baby products suggests that manufacturers and regulators should extend monitoring beyond well-known parental additives.

Exposure assessment: what detected concentrations mean for infants and toddlers

The study applied dermal exposure estimates specific to infants and toddlers, integrating measured concentrations with typical application behaviors and body weights. These calculations showed that estimated single-ingredient dermal exposures were generally low. Even so, the frequent detection of multiple PAs across product types raises two concerns: cumulative exposure (multiple chemicals acting across a single pathway) and mixture exposure (chemicals with different mechanisms affecting the same biological endpoints).

Why low individual estimates still matter:

Sensitive windows: Infancy is a period of rapid development for endocrine, neurological, and reproductive systems. Small perturbations by endocrine-active chemicals may carry outsized effects when they coincide with critical developmental windows.
Repeated dosing: Many baby products are used daily, sometimes multiple times a day. Chronic low-level dermal exposure accumulates over weeks and months.
Mixture effects: Co-exposure to multiple endocrine disruptors or neurotoxicants can produce additive or non-linear effects, even when each chemical is below a threshold of concern on its own.
Differences in skin absorption: Infant skin is thinner, has a higher surface area-to-body weight ratio, and may allow greater percutaneous absorption of certain chemicals. Some transformation products are more polar and may penetrate differently.

Quantitative dermal exposure estimates were not offered in the abstract for each chemical, but the medians provide a framework. For example, a median non-phthalate plasticizer concentration of 1,090 ng/g translates into microgram-level exposures per typical product application, depending on the amount applied. Translating ng/g into absorbed dose requires additional inputs: applied mass, fraction absorbed through skin, and frequency. The study concluded that single-chemical dermal exposures appear low, yet flagged the cumulative and mixture concerns as reasons for further evaluation.

Toxicological context: what is known about the health effects of detected groups

The chemical groups identified have different and sometimes overlapping toxicological profiles. Summaries follow, focusing on endpoints of particular concern for infants.

Phthalates (legacy): Certain phthalates (e.g., DEHP, DBP) are associated with reproductive development effects and have endocrine-disrupting activity. Regulatory actions have reduced their use in many cosmetics, but their historical and residual presence can persist in products and supply chains.
Non-phthalate plasticizers: Designed as alternatives, many non-phthalate plasticizers (e.g., DINCH, DPHP, adipates, citrate esters) have less extensive toxicological histories. Early data suggest lower potency for some endpoints, but comprehensive long-term and developmental studies are often lacking.
Organophosphate esters (OPEs): Used widely as flame retardants and plasticizers, OPEs include compounds such as triphenyl phosphate (TPHP) and tris(2-chloroethyl) phosphate (TCEP). Some OPEs exhibit neurodevelopmental toxicity and endocrine activity in experimental models. Dermal exposure is noteworthy because certain OPEs are semi-volatile and can partition to skin and clothing.
UV stabilizers and filters: Constituents such as benzophenone derivatives and benzotriazoles can have estrogenic or anti-androgenic effects in some assays. UV filters used in sunscreens have demonstrated percutaneous absorption and systemic presence. Stability under heat and light can lead to transformation products with distinct toxicities.
Synthetic antioxidants: Compounds like BHT (butylated hydroxytoluene) stabilize formulations and polymers. BHT and its metabolites have been studied for potential endocrine activity and other toxic effects; transformation products may present different biological profiles.
Parabens: Widely used preservatives that can exhibit weak estrogenic activity. Regulatory attention has reduced the use of some parabens, but low-level mixtures remain common.
Bisphenols: Bisphenol A (BPA) is a known endocrine disruptor. Replacement bisphenols (BPS, BPF) have been used widely and show overlapping endocrine activity in some studies.

The central toxicological concern is cumulative endocrine disruption. Many of these groups affect hormone signaling. When multiple compounds with such potential co-occur, additive risks become plausible even if individual concentrations are low. Other endpoints, notably neurodevelopment from OPEs and certain flame retardants, raise concern because exposures during early life can have lasting consequences.

Sources and pathways of contamination: how do plastic additives get into baby products?

Plastic additives can appear in baby skincare products through deliberate formulation choices or unintended contamination. Key pathways include:

Direct formulation: Some additives functionally belong in cosmetic formulations. Plasticizers or humectant additives might be chosen to modify texture. Antioxidants and UV stabilizers may be added to protect formulations or packaging.
Raw materials: Ingredients derived from petroleum or polymer processing can carry additive residues. For example, carrier oils, fragrances, and emollients may introduce trace additives if sourced from plastic-contact processes or recycled streams.
Packaging migration: Many additives migrate from plastic containers into contents. The extent of migration depends on additive mobility, polymer type, storage temperature, and product composition. Thin-skin lotions and oily formulations can facilitate transfer from plastics into the product.
Manufacturing and equipment: Shared processing lines or plastic tubing in manufacturing can introduce cross-contamination. Cleaning regimes, solvent residues, and inadvertent blending can move additives between batches.
Environmental contamination and transformation: Storage, transport, or exposure to light and heat can degrade parent chemicals into transformation products that end up in the final product. Additionally, recycled plastics used in packaging may carry legacy additives that leach into products.
Trace impurities in ingredient supply chains: Some additives are unintentionally produced during chemical synthesis or refining and end up as impurities in raw materials.

Understanding these pathways is essential to mitigation. For manufacturers, controlling raw material specifications, choosing inert packaging materials (e.g., glass or certain coated containers), managing production lines, and testing for migration can reduce PA presence. For regulators, knowing which pathways dominate can inform target points for intervention.

Regulatory landscape and gaps: how current rules align with findings

Cosmetics regulation varies across jurisdictions. A few regulatory realities are relevant:

Targeted bans and restrictions: Several jurisdictions restrict or ban particular phthalates and other high-concern additives in cosmetics. The European Union has limited or banned the use of many phthalates and certain UV filters. The U.S. Food and Drug Administration (FDA) regulates cosmetics less prescriptively and relies more on manufacturers for product safety, though some states have enacted stricter rules.
Replacement chemistry outpacing testing: As regulated chemicals are phased out, industry often adopts substitutes with less comprehensive safety data. These replacements can become ubiquitous before full toxicological profiles are established.
Limited oversight of transformation products: Regulatory testing tends to emphasize parent compounds named on ingredient lists. Transformation products — which can arise during production, storage, or use — are poorly covered by routine regulatory testing or labeling requirements.
Packaging migration rules: Some migration testing exists, particularly for food-contact materials. Cosmetic products have fewer harmonized migration standards, allowing packaging to be a less regulated source of contamination.
Cumulative and mixture risk assessment: Most regulatory frameworks assess chemicals individually. Few require explicit mixture risk assessments that reflect real-world exposure to multiple endocrine-active chemicals, especially during sensitive developmental periods.

These gaps mean that low-level but widespread mixtures of PAs in baby products can exist without triggering regulatory action, even though biological plausibility for combined effects remains.

Industry implications: formulation, testing, and supply chain management

For manufacturers the findings carry practical implications:

Ingredient transparency: Many consumers expect clear labeling, but not all contaminants are listed. Disclosing functional additives and potential trace contaminants can rebuild trust and enable informed choices.
Supplier specifications: Tightening raw material specifications and testing requirements reduces the likelihood of introducing unwanted PAs. Suppliers should certify absence of certain high-risk residues and provide testing data.
Packaging choices: Switching to non-plastic alternatives, barrier-coated containers, or multi-layer laminates can reduce migration. Packaging should be evaluated not only for primary function but for potential to contribute contaminants.
Manufacturing controls: Segregating lines for products intended for infants, using inert materials in contact points, and validating cleaning procedures mitigate cross-contamination risks.
Analytical monitoring: Routine screening for a broader suite of PAs, including suspect screening for transformation products, should be part of quality assurance programs. Investing in non-targeted analytic capacity can catch unexpected contaminants early.
Safer substitution: Replacements should be selected based on robust hazard assessments, not solely on whether they’re excluded from existing lists. Alternatives assessment frameworks that include life-cycle considerations will identify truly safer options.

Example: A manufacturer choosing to move from plastic-lined pump bottles to glass dispensers observed a measurable drop in specific OPEs and plasticizer residues. Another company instituted supplier audits that identified a raw oil supplier introducing low-level UV stabilizer residues through tank contamination; switching suppliers eliminated recurrent detections.

Consumer guidance: practical steps parents can take now

Parents can reduce exposure to plastic additives in several pragmatic ways without abandoning personal care routines that soothe and protect a child’s skin.

Check product labels for known additions: Ingredients such as parabens, BHT, and certain conspicuously named plasticizers may be listed. Absence of particular names does not guarantee absence of contaminants, but label choices can narrow the field.
Choose simple formulations: Products with fewer ingredients reduce the potential for unintended contaminants. Fragrance-free and minimalist formulations often carry lower additive loads.
Prefer credible third-party testing or certifications: Look for brands that disclose independent testing for contaminants or that maintain rigorous quality-control programs targeted at infant products.
Consider packaging: Glass or pump dispensers with minimal plastic contact reduce migration risk. For travel-size products or frequent-use items, choosing glass where practical may cut exposure.
Limit frequency and quantity when safe: For non-essential uses, reducing application frequency lowers cumulative exposure. For necessary uses like moisturizing and diaper-area products, moderate application consistent with pediatric guidance remains important.
Wash hands after application when appropriate: Parents handling product applicators or a baby’s body may reduce transfer to their own skin and the household environment.

These steps lower, but do not eliminate, exposure. Broader reductions will depend on industry changes and regulatory action.

Research needs: where science must advance

The study pinpoints several areas where additional research will clarify risk and guide policy:

Toxicity of transformation products: Systematic toxicological evaluation of the transformation products identified is necessary. Those derivatives may display different potency or target endpoints than parent compounds.
Mixture and cumulative effects: Experimental and epidemiological studies should address whether low-level mixtures of endocrine-active and neurotoxic compounds produce additive or synergistic effects in early life.
Dermal absorption in infants: Quantitative absorption studies that account for infant skin properties, occlusion by clothing or diapers, and formulation-specific penetration enhancers will refine exposure and risk estimates.
Longitudinal exposure tracking: Biomonitoring studies of infants and toddlers matched to product use records can connect product chemicals to internal doses and outcomes.
Source apportionment: Tracing the pathways by which PAs enter formulations — packaging migration studies, supply-chain audits, and manufacturing contamination source-tracking — will inform practical mitigation strategies.
Improved analytics and standardization: Wider availability of reference standards for emerging plasticizers and transformation products will permit targeted quantification, while harmonized suspect-screening libraries will improve comparability across studies.

Filling these gaps will require collaboration across academia, industry, and regulators, given the interdisciplinary nature of the challenge.

Policy options: reducing exposure at the population level

Policy levers can shape market behavior and reduce population-level exposure to PAs in infant products. Potential actions include:

Expand regulated lists: Updating regulations to include emerging plasticizers and classes of transformation products when sufficient hazard evidence accumulates.
Require migration and contaminant testing for infant products: Mandated testing for plastics-related contaminants and transformation products, with thresholds tailored to sensitive populations.
Strengthen labeling and transparency requirements: Requiring ingredient and additive disclosure, and potentially reporting of suspect-screening outcomes for infant-specific products.
Adopt mixture risk frameworks: Incorporating cumulative and mixture assessment in safety evaluations for products intended for infants and pregnant people.
Promote safer-by-design and substitution incentives: Financial or regulatory incentives that lower barriers to adopting thoroughly tested, safer alternatives.
Harmonize international standards: Many product supply chains are global; harmonized rules prevent lower-standard jurisdictions from becoming sources of contaminated ingredients or packaging.

Implementing these measures requires balancing innovation and precaution. Policy interventions should prioritize children’s health and the best available science on sensitive endpoints.

What manufacturers and regulators should monitor routinely

Given the study’s findings, recommended routine surveillance would include:

A core panel of PAs that covers phthalates, representative non-phthalate plasticizers, organophosphate esters, UV stabilizers, antioxidants, bisphenols, and parabens.
Periodic suspect screening to detect new or unexpected transformation products.
Migration testing of packaging into representative product matrices under storage and use conditions.
Batch-level verification for infant-specific product lines, with clear rejection criteria for contaminated batches.
Public reporting of surveillance outcomes for infant-targeted products, to foster accountability and informed consumer choice.

Adoption of a tiered monitoring program — routine targeted testing plus periodic non-targeted sweeps — will catch both known contaminants and emergent threats.

Balancing benefits and uncertainties: practical risk communication

Communicating about chemical detections in items used for infants requires care. Statements should emphasize the measured facts, contextualize exposure levels, and provide actionable steps for risk reduction without provoking unnecessary alarm.

Key messages must be clear:

Detection does not equate to immediate harm. Measured concentrations were generally low on a per-ingredient basis.
The concern arises from mixture exposures and sensitive developmental windows. Even low-level exposures can be relevant in aggregate.
Practical steps can lower exposure today while policy and industry measures address broader sources.

Messages that combine factual findings with pragmatic consumer guidance and advocacy for stronger safety systems will serve families best.

Closing observations: the study’s contribution to product safety science

This comprehensive chemical inventory reframes how product safety is assessed for infant skincare. It demonstrates that baby formulations can bear a complex mix of plastic additives, including many not previously reported in such products. The discovery of transformation products is especially important because it reveals chemical complexity beyond standard ingredient lists. The research underscores the need to expand analytical horizons, consider mixture and life-cycle exposures, and target policies toward the sources that introduce these chemicals into infant products.

Expect future work to build on these results by widening geographic and product coverage, linking product use to biomonitoring, and characterizing the toxicology of newly identified compounds. For now, manufacturers, regulators, and caregivers have a clearer map of where and how plastic additives appear in infant skincare — and a stronger basis for informed decisions to reduce exposure and protect developing children.

FAQ

Q: Are the detected levels of plastic additives dangerous for babies? A: The study estimated that single-chemical dermal exposures were generally low. That does not rule out concern. The primary issues are cumulative and mixture exposures across multiple products and chemicals, and the heightened sensitivity of infants and toddlers during development. Scientific certainty about long-term effects from combined low-dose exposures remains incomplete.

Q: Which product types had the highest concentrations of plastic additives? A: The study found product-specific patterns. Lotions commonly had higher levels of non-phthalate plasticizers and antioxidants; powders sometimes showed higher relative content of UV stabilizers or organophosphate residues. However, concentrations varied widely between individual products within each category.

Q: Were any banned phthalates still found in the products? A: The abstract reports detection of phthalate esters as a group with a median concentration of 205 ng/g. It does not specify which phthalates, so whether regulated/phased-out phthalates were present cannot be concluded from the abstract alone. Full study data would clarify the identities of detected phthalates.

Q: What are transformation products and why do they matter? A: Transformation products form when parent chemicals break down through chemical, photochemical, or biological processes during production, storage, or use. They matter because they can have different toxicity, mobility, and persistence compared with parental compounds. Regulatory testing and labeling often do not capture these derivatives, leaving gaps in risk assessment.

Q: Can packaging contribute to contamination? A: Yes. Plastic packaging can leach additives into product contents. Migration depends on the additive’s properties, the polymer, the product matrix (oily vs. aqueous), storage time, and temperature. Choosing inert packaging or using robust barrier systems reduces migration risk.

Q: How can parents reduce exposure to these chemicals today? A: Practical steps include choosing simpler formulations with fewer ingredients, preferring fragrance-free products, selecting packaging types that minimize plastic contact (e.g., glass), and buying from manufacturers that publish independent contaminant testing. Reducing frequency or quantity of non-essential product use can also lower cumulative exposure.

Q: Should regulators ban all plastic additives in baby products? A: Blanket bans may not be feasible or necessary; many additives serve functional purposes and are safe when used appropriately. Targeted restrictions on high-hazard chemicals, enhanced surveillance for transformation products and mixtures, improved labeling, and stronger migration testing are policy options that strike a balance between utility and protection of sensitive populations.

Q: What should manufacturers do next? A: Manufacturers should expand testing to include suspect screening for transformation products, tighten supplier specifications, evaluate packaging alternatives, implement segregation and cleaning protocols to limit cross-contamination, and adopt substitution processes that prioritize well-characterized, lower-hazard alternatives.

Q: Where can I find more information about the specific chemicals detected? A: The study’s full text and supporting materials typically list the confirmed and quantified compounds. Those documents will provide chemical identities and concentration ranges for each detected PA. For broader context on health effects, agencies such as national public health agencies and international bodies publish summaries of toxicity for common additives like phthalates, bisphenols, organophosphates, parabens, and UV filters.

Q: What research is needed to clarify health risks? A: Priority research includes toxicological characterization of transformation products, studies addressing mixture effects at environmentally relevant doses, infant-specific dermal absorption studies, biomonitoring linked to product use, and source-apportionment work to trace how contaminants enter formulations and packaging.